Review

October 2, 2024


Roles of X-box binding protein 1 in liver pathogenesis
Jihoon Tak, Yun Seok Kim, Sang Geon Kim
Clin Mol Hepatol. 2025;31(1):1-31.

Review

October 2, 2024


Sinusoidal communication in chronic liver disease
Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, et al.
Clin Mol Hepatol. 2025;31(1):32-55.

Review

October 21, 2024


Bioactive metabolites: A clue to the link between MASLD and CKD?
Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, et al.
Clin Mol Hepatol. 2025;31(1):56-73.

Review

October 23, 2024


Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, et al.
Clin Mol Hepatol. 2025;31(1):74-89.

Review

November 11, 2024


Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment
Atsumasa Komori, Yuki Kugiyama
Clin Mol Hepatol. 2025;31(1):90-104.

Original Article

July 11, 2024


Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
Chuan Liu, Hong You, Qing-Lei Zeng, et al.
Clin Mol Hepatol. 2025;31(1):105-118.

Original Article

September 24, 2024


Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial
Woo Hyun Paik, Joo Kyung Park, Moon Jae Chung, et al.
Clin Mol Hepatol. 2025;31(1):119-130.

Original Article

October 2, 2024


Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation
Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, et al.
Clin Mol Hepatol. 2025;31(1):131-146.

Original Article

October 2, 2024


USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination
Sha Hu, Zhouxiang Wang, Kun Zhu, et al.
Clin Mol Hepatol. 2025;31(1):147-165.

Original Article

October 4, 2024


Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, et al.
Clin Mol Hepatol. 2025;31(1):166-178.

Original Article

October 11, 2024


Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments
Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, et al.
Clin Mol Hepatol. 2025;31(1):179-195.

Original Article

October 15, 2024


Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma
Yang Liu, Fan Peng, Siyuan Wang, et al.
Clin Mol Hepatol. 2025;31(1):196-212.

Original Article

October 17, 2024


Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial
Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, et al.
Clin Mol Hepatol. 2025;31(1):213-226.

Original Article

November 14, 2024


Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis
Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, et al.
Clin Mol Hepatol. 2025;31(1):227-239.

Original Article

November 21, 2024


Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis
Anja Tiede, Lena Stockhoff, Zhaoli Liu, et al.
Clin Mol Hepatol. 2025;31(1):240-255.


Review
2048
Roles of X-box binding protein 1 in liver pathogenesis
Jihoon Tak, Yun Seok Kim, Sang Geon Kim
Clin Mol Hepatol. 2025;31(1):1-31.   Published online October 2, 2024
View: 1216   Download: 127
2050
Sinusoidal communication in chronic liver disease
Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, Pablo Alfaro-Retamero, Sergi Guixé-Muntet, Jordi Gracia-Sancho
Clin Mol Hepatol. 2025;31(1):32-55.   Published online October 2, 2024
View: 970   Download: 179
2073
Bioactive metabolites: A clue to the link between MASLD and CKD?
Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun
Clin Mol Hepatol. 2025;31(1):56-73.   Published online October 21, 2024
View: 1091   Download: 143
2076
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim
Clin Mol Hepatol. 2025;31(1):74-89.   Published online October 23, 2024
View: 1765   Download: 288  Crossref: 6
2093
Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment
Atsumasa Komori, Yuki Kugiyama
Clin Mol Hepatol. 2025;31(1):90-104.   Published online November 11, 2024
View: 749   Download: 150
Original Article
1968
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Federico Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi
Clin Mol Hepatol. 2025;31(1):105-118.   Published online July 11, 2024
View: 1892   Download: 237  Crossref: 1
2045
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial
Woo Hyun Paik, Joo Kyung Park, Moon Jae Chung, Gunn Huh, Ce Hwan Park, Sang Hyub Lee, Heon Se Jeong, Hee Jin Kim, Do Hyun Park
Clin Mol Hepatol. 2025;31(1):119-130.   Published online September 24, 2024
View: 871   Download: 173
2049
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation
Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi
Clin Mol Hepatol. 2025;31(1):131-146.   Published online October 2, 2024
View: 859   Download: 144
2051
USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination
Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li
Clin Mol Hepatol. 2025;31(1):147-165.   Published online October 2, 2024
View: 1891   Download: 477
2052
Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
Clin Mol Hepatol. 2025;31(1):166-178.   Published online October 4, 2024
View: 738   Download: 88
2066
Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments
Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian
Clin Mol Hepatol. 2025;31(1):179-195.   Published online October 11, 2024
View: 878   Download: 115
2069
Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma
Yang Liu, Fan Peng, Siyuan Wang, Huanmin Jiao, Kaixiang Zhou, Wenjie Guo, Shanshan Guo, Miao Dang, Huanqin Zhang, Weizheng Zhou, Xu Guo, Jinliang Xing
Clin Mol Hepatol. 2025;31(1):196-212.   Published online October 15, 2024
View: 812   Download: 133  Crossref: 1
2071
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial
Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, Chieh-Chang Chen, Teng-Yu Lee, Ming-Jong Bair, Jyh-Jou Chen, Yen-Tsung Huang, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Ming-Shiang Wu, Lein-Ray Mo, Jaw-Town Lin
Clin Mol Hepatol. 2025;31(1):213-226.   Published online October 17, 2024
View: 698   Download: 98
2101
Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis
Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2025;31(1):227-239.   Published online November 14, 2024
View: 824   Download: 78
2102
Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis
Anja Tiede, Lena Stockhoff, Zhaoli Liu, Hannah Rieland, Jim B. Mauz, Valerie Ohlendorf, Birgit Bremer, Jennifer Witt, Anke Kraft, Markus Cornberg, Jan B. Hinrichs, Bernhard C. Meyer, Heiner Wedemeyer, Cheng-Jian Xu, Christine S. Falk, Benjamin Maasoumy
Clin Mol Hepatol. 2025;31(1):240-255.   Published online November 21, 2024
View: 682   Download: 121  Crossref: 1
Identification of KCTD17 as a Ras stabilizer in hepatocellular carcinoma: Editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”
Rainbow Wing Hei Leung, Terence Kin Wah Lee
Clin Mol Hepatol. 2025;31(1):304-307.   Published online August 30, 2024
View: 549   Download: 33
Snapshot
1993
Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues
Clara Meda, Arianna Dolce, Sara Della Torre
Clin Mol Hepatol. 2025;31(1):327-332.   Published online August 5, 2024
View: 519   Download: 57
Letter to the Editor
Accountability in AI medicine: A critical appraisal of ChatGPT in patient self-management and screening
Jiawen Wang, Tian Xia
Clin Mol Hepatol. 2025;31(1):e1-e2.   Published online September 26, 2024
View: 449   Download: 37
Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li
Clin Mol Hepatol. 2025;31(1):e3-e4.   Published online October 7, 2024
View: 499   Download: 39
2060
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
Donghee Kim, Won Kim, Aijaz Ahmed
Clin Mol Hepatol. 2025;31(1):e5-e7.   Published online October 8, 2024
View: 424   Download: 27
Insights on risk score development: Considerations for early-stage hepatocellular carcinoma models
Zhanna Zhang, Gongqiang Wu
Clin Mol Hepatol. 2025;31(1):e8-e9.   Published online November 6, 2024
View: 376   Download: 20
Grading severity of microvascular invasion in hepatocellular carcinoma: More details, more significance
Xiu-Ping Zhang, Fei-Fan Wu, Tian-Chen Zhang, Zhen-Qi Li, Ming-Gen Hu, Rong Liu
Clin Mol Hepatol. 2025;31(1):e10-e12.   Published online November 26, 2024
View: 409   Download: 45
Letter to the editor on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
Meng-Che Wu, Hui-Chin Chang, Yi-Sheng Jhang, Shuo-Yan Gau
Clin Mol Hepatol. 2025;31(1):e13-e14.   Published online September 2, 2024
View: 751   Download: 78
Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma
Xiping Shen, Ji Wu
Clin Mol Hepatol. 2025;31(1):e17-e18.   Published online October 11, 2024
View: 588   Download: 41
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs
Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau
Clin Mol Hepatol. 2025;31(1):e19-e20.   Published online October 17, 2024
View: 388   Download: 23
Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”
Wei Feng, Qile Wang, Qingwang Ye
Clin Mol Hepatol. 2025;31(1):e21-e22.   Published online October 11, 2024
View: 524   Download: 22
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus
Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng
Clin Mol Hepatol. 2025;31(1):e23-e24.   Published online November 26, 2024
View: 302   Download: 13
The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread
Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang
Clin Mol Hepatol. 2025;31(1):e25-e26.   Published online December 10, 2024
View: 373   Download: 32
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu
Clin Mol Hepatol. 2025;31(1):e31-e34.   Published online September 20, 2024
View: 631   Download: 84  Crossref: 1
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen
Clin Mol Hepatol. 2025;31(1):e35-e38.   Published online September 20, 2024
View: 559   Download: 53
2077
Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China
Lei Cai, Chao Li, Li-Yang Sun, Yong-Kang Diao, Ming-Da Wang, Tian Yang
Clin Mol Hepatol. 2025;31(1):e39-e43.   Published online October 23, 2024
View: 449   Download: 43
Correspondence
Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
Shunda Du, Karin Wisskirchen, Ke Zhang, Ulrike Protzer
Clin Mol Hepatol. 2025;31(1):e44-e47.   Published online October 21, 2024
View: 585   Download: 35
2035
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
Hee Yeon Kim, Miyoung Choi, Dae Won Jun
Clin Mol Hepatol. 2025;31(1):e48-e51.   Published online September 11, 2024
View: 420   Download: 20
1989
Correspondence to editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”
Renyu Zhang, Ding Wei, Zhinan Chen, Huijie Bian
Clin Mol Hepatol. 2025;31(1):e58-e60.   Published online July 29, 2024
View: 564   Download: 47
Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”
Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim
Clin Mol Hepatol. 2025;31(1):e70-e73.   Published online September 10, 2024
View: 486   Download: 38
Correspondence to editorial on: “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”
Satya Priya Sharma, Ki Tae Suk
Clin Mol Hepatol. 2025;31(1):e74-e77.   Published online October 15, 2024
View: 663   Download: 37
Correspondence to editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”
Sang Bae Lee, KyeongJin Kim
Clin Mol Hepatol. 2025;31(1):e78-e80.   Published online September 10, 2024
View: 541   Download: 55
Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee
Clin Mol Hepatol. 2025;31(1):e81-e83.   Published online October 7, 2024
View: 491   Download: 25
Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee
Clin Mol Hepatol. 2025;31(1):e84-e86.   Published online October 7, 2024
View: 444   Download: 18
Correspondence to editorial on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: a multinational population-based cohort study from South Korea, Japan, and the UK”
Kwanjoo Lee, Jaeyu Park, Jinseok Lee, Hayeon Lee, Yeonjung Ha, Dong Keon Yon
Clin Mol Hepatol. 2025;31(1):e87-e89.   Published online October 29, 2024
View: 354   Download: 10
Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”
Yu-Hang Ye, Shao-Lai Zhou
Clin Mol Hepatol. 2025;31(1):e90-e92.   Published online November 11, 2024
View: 365   Download: 12
Correspondence to letter to the editor 1 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su
Clin Mol Hepatol. 2025;31(1):e96-e97.   Published online November 11, 2024
View: 310   Download: 8
Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol. 2025;31(1):e98-e100.   Published online October 21, 2024
View: 448   Download: 31
Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”
Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su
Clin Mol Hepatol. 2025;31(1):e101-e102.   Published online November 6, 2024
View: 318   Download: 10
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
Hee Yeon Kim, Miyoung Choi, Dae Won Jun
Clin Mol Hepatol. 2025;31(1):e105-e107.   Published online November 4, 2024
View: 311   Download: 16
Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”
Gi-Ae Kim, Seung Won Choi, Young-Suk Lim
Clin Mol Hepatol. 2025;31(1):e108-e109.   Published online August 5, 2024
View: 467   Download: 26
Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee
Clin Mol Hepatol. 2025;31(1):e110-e112.   Published online October 2, 2024
View: 514   Download: 36
Reply to Correspondence
2061
Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
Antonio Bertoletti, Anthony T Tan
Clin Mol Hepatol. 2025;31(1):e113-e116.   Published online October 11, 2024
View: 557   Download: 23
Reply to correspondence on “UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma”
Martina Mang Leng Lei, Terence Kin Wah Lee
Clin Mol Hepatol. 2025;31(1):e119-e120.   Published online August 5, 2024
View: 472   Download: 25

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 5673
TOTAL : 2380345
Close layer